The subdued stock price reaction suggests that Merck & Co., Inc.'s (NYSE:MRK) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors underlying ...

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce ...

She regularly appears on CBS News 24/7 to discuss her reporting. Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall Street expectations and the company raised its revenue outlook for ...